|
Glenn joined ActivBiotics in the fall of 2004 as Chief Business Officer. Glenn has over 20 years of experience in the BioPharmaceutical/Medical Device industry as a senior executive, corporate officer and scientist with extensive financing, business development, marketing and strategic planning experience. He has significant experience in all facets of private and public biotech financing with a well established network of investors, and bankers/analysts. He has been intimately involved in taking three biotech companies public, two on NASDAQ and one on London Stock Exchange. He helped found Enzon, Inc., in 1981, now a $500 Million market valuation specialty drug company. Most recently, Glenn was Chief Business Officer and General Manager of US operations at XTL Biopharaceuticals, Inc. as well as a member of their Board of Directors. Glenn also serves on the Board of Directors of Prolong Pharmaceuticals, a development stage biogeneric pharmaceutical company. | 